Table 3 Microbiologic data and treatment
Variablea | Intravenous colistin only (n = 51) | Intravenous + aerosolized colistin (n = 44) | p-value |
|---|---|---|---|
Respiratory source, n (%) | |||
Bronchoalveolar lavage | 32 (62.7) | 35 (79.5) | 0.113 |
Sputum/tracheal aspirate | 19 (37.3) | 9 (20.5) | 0.113 |
Respiratory isolatesb | |||
Acinetobacter spp. | 25 (49.0) | 36 (81.8) | 0.001 |
Pseudomonas spp. | 35 (68.6) | 18 (40.9) | 0.007 |
ESBL Klebsiella spp. | 9 (17.6) | 2 (4.5) | 0.047 |
Other site of infection | |||
Blood | 10 (19.6) | 14 (31.8) | 0.172 |
Urine | 9 (17.6) | 6 (13.6) | 0.593 |
SSTI | 4 (7.8) | 4 (9.1) | >0.99 |
Other | 5 (9.8) | 1 (2.3) | 0.211 |
Additional coverage with colistin | 33 (64.7) | 19 (43.2) | 0.036 |
Tigecycline | 7 (21.2) | 9 (42.9) | 0.089 |
Aminoglycoside | 8 (24.2) | 3 (14.3) | 0.497 |
Carbapenem | 13 (39.4) | 5 (23.8) | 0.236 |
Piperacillin/tazobactam | 3 (9.1) | 0 | 0.274 |
Ampicillin/sulbactam | 1 (3.0) | 2 (9.5) | 0.553 |
Cefepime | 5 (15.2) | 1 (4.8) | 0.386 |
Ciprofloxacin | 1 (3.0) | 1 (4.8) | >0.99 |
Intravenous colistin dosing | |||
Total daily dose IBW (mg/kg) | 3.7 ± 2.1 | 4 ± 2.3 | 0.596 |
Total daily dose TBW (mg/kg) | 2.5 ± 1.5 | 2.6 ± 1.4 | 0.654 |
Time to appropriate therapy (days), median [IQR] | 4 [3–6.25] | 4 [3–5.75] | 0.625 |
Duration of intravenous colistin (days) | 11.2 ± 7.7 | 12.2 ±7.2 | 0.529 |
Total intravenous dose (mg), median [IQR] | 2100 [700–4200] | 2002.5 [1080–4200] | 0.407 |
Adequate initial intravenous dosing | 38 (74.5) | 33 (77.3) | 0.754 |
Aerosolized colistin dosing | |||
Total daily dose (mg), median [IQR] | 75 [75–75] | NA | |
Duration (days), median [IQR] | 11.0 [7–16.25] | NA |